anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The development of laparoscopic liver surgery, the improvement in the perioperative care programs, and the surgical innovation have allowed liver resections on selected cirrhotic patients. However, the great majority of ERAS studies for liver surgery have been conducted on patients with normal liver parenchyma, while its application on cirrhotic patients is limited. The purpose of this study was to evaluate the implementation of an ERAS protocol in cirrhotic patients who underwent liver surgery. We present an analytical observational prospective cohort study, which included all adult patients who underwent a liver resection between December 2017 and December 2019 with an ERAS program. We compare the outcomes in patients cirrhotic (CG)/non-cirrhotic (NCG). A total of 101 patients were included. Thirty of these (29.7%) were patients ≥ 70 cirrhotic. 87% of the both groups had performed > 70% of the ERAS. Oral diet tolerance and mobilization on the first postoperative day were similar in both groups. The hospital stay was similar in both groups (2.9 days/2.99 days). Morbidity and mortality were similar; Clavien I-II (CG: 44% vs NCG: 30%) and Clavien ≥ III (CG: 3% vs NCG: 8%). Hospital re-entry was higher in the NCG. Overall mortality of the study was 1%. ERAS protocol compliance was associated with a decrease in complications (ERAS < 70%: 80% vs ERAS > 90%: 20%; p: 0.02) and decrease in severity of complications in both study groups. The application of the ERAS program in cirrhotic patients who undergo liver surgery is feasible, safe, and reproducible. It allows postoperative complications, mortality, hospital stay, and readmission rates comparable to those in standard patients.
Cancer metabolism mainly includes carbohydrate, amino acid and lipid metabolism, each of which can be reprogrammed. These processes interact with each other to adapt to the complicated microenvironment. Ferroptosis is a regulated cell death induced by iron-dependent lipid peroxidation, which is morphologically different from apoptosis, necrosis, necroptosis, pyroptosis, autophagy-dependent cell death and cuprotosis. Cancer metabolism plays opposite roles in ferroptosis. On the one hand, carbohydrate metabolism can produce NADPH to maintain GPX4 and FSP1 function, and amino acid metabolism can provide substrates for synthesizing GPX4; on the other hand, lipid metabolism might synthesize PUFAs to trigger ferroptosis. The mechanisms through which cancer metabolism affects ferroptosis have been investigated extensively for a long time; however, some mechanisms have not yet been elucidated. In this review, we summarize the interaction between cancer metabolism and ferroptosis. Importantly, we were most concerned with how these targets can be utilized in cancer therapy.
Retinol is a fat-soluble vitamin that plays an essential role in many biological processes throughout the human lifespan. Here, we perform the largest genome-wide association study (GWAS) of retinol to date in up to 22,274 participants. We identify eight common variant loci associated with retinol, as well as a rare-variant signal. An integrative gene prioritisation pipeline supports novel retinol-associated genes outside of the main retinol transport complex (RBP4:TTR) related to lipid biology, energy homoeostasis, and endocrine signalling. Genetic proxies of circulating retinol were then used to estimate causal relationships with almost 20,000 clinical phenotypes via a phenome-wide Mendelian randomisation study (MR-pheWAS). The MR-pheWAS suggests that retinol may exert causal effects on inflammation, adiposity, ocular measures, the microbiome, and MRI-derived brain phenotypes, amongst several others. Conversely, circulating retinol may be causally influenced by factors including lipids and serum creatinine. Finally, we demonstrate how a retinol polygenic score could identify individuals more likely to fall outside of the normative range of circulating retinol for a given age. In summary, this study provides a comprehensive evaluation of the genetics of circulating retinol, as well as revealing traits which should be prioritised for further investigation with respect to retinol related therapies or nutritional intervention.
PURPOSE: To obtain the hair-treating agent composition containing a specific N-alkyl-2-amino-3-mercaptopropionic acid amide derivative or its salt as a reducing agent, having an excellent waving effect and an excellent wave-holding property, and also high in safety. CONSTITUTION: The hair-treating agent contains an N-alkyl-2-amino-3- mercaptopropionic acid amide derivative of formula 1 (R<1> is 1-4C alkyl) or its salt. Either of the (R) isomer, racemic isomers and (S) isomer of the compound of formula 1 may be used as the compound of formula 1. The compound of formula 1 is obtained e.g. by reacting a cysteine alkyl ester of formula 2 (R<2> is lower alkyl) or its salt with an amine of formula 3. The composition has an excellent waving effect, an excellent wave-holding property, a low hair- damaging property, a low smelling property, a low flaking property, and high safety, and is useful as the first agent for a permanent-waving agent or as the first agent for a curly hair-correcting agent.
Different medications last for different amounts of time and can be changed depending on the length of the procedure. A short acting spinal is generally used for procedures lasting less than 90 minutes. A longer acting medication would be any that lasts longer than 90 minutes. These medications not only block the signals that travel along the pain nerves, they also prevent the signals that tell the patients muscles to move. This means that after a total knee replacement a patient may delayed in their ability to get up and start walking early after surgery. Walking early in the recovery has been shown to decrease the rate of pulmonary embolism and death. Ambulating early is also important to prevent loss of strength, constipation, pneumonia and urinary retention.
FIELD: medicine, medicinal genetics. SUBSTANCE: invention relates to "humanized" antibodies able to bind with human GP39. These antibodies can be used for treatment of autoimmune diseases and as immunodepressants in transplantation of heterologous cells, tissues or organs. Invention comprises variable sequences of indicated antibodies and corresponding pharmaceutical compositions comprising thereof. EFFECT: expanded assortment of agents for genetic therapy. 34 cl, 3 tbl, 26 dwg, 17 ex
Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
The control group will follow a conventional rehabilitation program (Egstrup et al 2015). The control subjects will participate in medicine titration for 1- 3 months and conventional rehabilitation for 3 months. The participation in the control group will last up to six months. The exact period depends on how fast the titration of medicine is conducted. At enrolment, after titration of medicine, and end of rehabilitation, the patient will fill in a questionnaire. This will take 5 minutes each time.
This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
PURPOSE: Although effective amblyopia treatments are available, treatment outcome is unpredictable, and the condition recurs in up to 25% of the patients. We aimed to evaluate whether a large-scale quantitative contrast sensitivity function (CSF) data source, coupled with machine learning (ML) algorithms, can predict amblyopia treatment response and recurrence in individuals.
METHODS: Visual function measures from traditional chart vision acuity (VA) and novel CSF assessments were used as the main predictive variables in the models. Information from 58 potential predictors was extracted to predict treatment response and recurrence. Six ML methods were applied to construct models. The SHapley Additive exPlanations was used to explain the predictions.
RESULTS: A total of 2559 consecutive records of 643 patients with amblyopia were eligible for modeling. Combining variables from VA and CSF assessments gave the highest accuracy for treatment response prediction, with the area under the receiver operating characteristic curve (AUC) of 0.863 and 0.815 for outcome predictions after 3 and 6 months, respectively. Variables from the VA assessment alone predicted the treatment response, with AUC values of 0.723 and 0.675 after 3 and 6 months, respectively. Variables from the CSF assessment gave rise to an AUC of 0.909 for recurrence prediction compared to 0.539 for VA assessment alone, and adding VA variables did not improve predictive performance. The interocular differences in CSF features are significant contributors to recurrence risk.
CONCLUSIONS: Our models showed CSF data could enhance treatment response prediction and accurately predict amblyopia recurrence, which has the potential to guide amblyopia management by enabling patient-tailored decision making.
The safety and effectiveness of any spinal anesthetic depend upon proper dosage, correct technique, adequate precautions, and readiness for emergencies. The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious systemic side effects. Tolerance varies with the status of the patient; debilitated, elderly patients or acutely ill patients should be given reduced doses commensurate with their weight, age, and physical status. Reduced doses are also indicated for obstetric patients and those with increased intra-abdominal pressure.

Caution should be used in administering tetracaine hydrochloride to patients with abnormal or reduced levels of plasma esterases.

Blood pressure should be frequently monitored during spinal anesthesia and hypotension immediately corrected.

Spinal anesthetics should be used with caution in patients with severe disturbances of cardiac rhythm, shock, and heartblock.
Objective: To examine sleep duration at admission and discharge and change in sleep duration during hospitalization in patients experiencing a manic episode and compare these parameters to patients hospitalized for major depressive disorder (MDD) during the same time frame. The correlation between sleep duration parameters in those with mania and MDD with length of hospital stay, after accounting for possible confounders, was also examined. Methods: This retrospective study examined patients admitted to an acute care psychiatric unit from 2018 to 2021 with an episode of mania or MDD. Sleep duration was determined based on nursing observer report. Results: The study included 41 patients with mania (32.9 ± 1.7 years) and 38 patients with MDD (32.7 ± 1.8 years). Mania patients had longer hospitalization and received higher antipsychotic and benzodiazepine doses, but fewer hypnotics (all P < .005). No differences were found in sleep duration at admission (P = .109) and discharge (P = .623) in the mania and MDD groups. Change in sleep duration was 1.14 ± 0.27 and 0.37 ± 0.28 hours (P = .05) in the groups, respectively. In those with mania, sleep duration at admission negatively correlated with length of stay (r = -0.033; P = .03). Sleep duration parameters were not correlated with length of stay in patients with MDD. Conclusion: There was a trend toward greater improvement in sleep duration in inpatients with mania versus MDD. Sleep duration at admission correlated with length of hospitalization in patients with mania. Future studies should examine whether attempts to increase sleep duration can improve patient outcomes. Prim Care Companion CNS Disord 2024;26(1):23m03620. Author affiliations are listed at the end of this article.
PROBLEM TO BE SOLVED: To alleviate time and labor required for work of managing pharmaceutical preparations used in a medical front and to prevent omission in the charge of fees of used pharmaceutical preparations, omission in replenishment of a pharmaceutical preparations storage with pharmaceutical preparations, etc.SOLUTION: A pharmaceutical preparation storage unit stores therein a plurality of types of pharmaceutical preparation codes allocated to respective pharmaceutical preparations. A slip storage unit stores therein types of preparation codes necessary for each of applications according to application of slips for notifying used pharmaceutical preparation information in a medical front. Identification means identifies a pharmaceutical preparation used in the medical front. Registration means registers information relating to the pharmaceutical preparation identified by the identifying means. Creation means acquires the pharmaceutical preparation code of the pharmaceutical preparation registered by the registration means for each of slips different in application from the pharmaceutical preparation storage unit and creates a slip according to application on the basis of the information stored in the slip storage unit. Output means outputs the slip according to application created by the creating means.
PURPOSE:To provide an antitumor agent containing cercosporin as an active component, having selective activity to inhibit protein kinase C and effective in inhibiting the growth of cancer cells. CONSTITUTION:The objective agent contains cercosporin as an active component. Cercosporin is a weak antibiotic substance and produced by conventional process from a microbial strain belonging to genus Cercospora. The composition can be administered, according to the purpose and method of administration, in the form of tablet, granule, powder, capsule, etc., prepared by conventional method. In the case of tablet, the amount of the active component is preferably 50-2,000mg in one tablet. The rate of administration is 0.25-100mg/kg in the case of intravenous injection.
Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position \& before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
The present invention relates to a deceleration assembly considering a patient treatment location. More specifically, by improving a front surface region of the deceleration assembly, the treatment area of a patient can be as close as possible to a beam port where neutrons are emitted, when treating the patient. Accordingly, a treating effect can be improved. A posture can be maintained so that the patient can feel comfortable during a treatment process. A deceleration assembly used to treat cancer in a boron neutron capture scheme according to the present invention has an outer shape of an enclosure, and a treatment posture spatial part of a certain depth is formed inside the lower portion of the beam port from which a neutron beam for treatment is emitted. Accordingly, a patient′s knee can be positioned thereat.
The present invention relates to a food composition for alleviating arteriosclerosis containing 7,8,4-trihydroxyisoflavone or a derivative thereof as an active ingredient, and to a pharmaceutical composition for preventing and treating arteriosclerosis. More specifically, the present invention relates to a food or pharmaceutical composition which can inhibit the progress of arteriosclerosis based on inflammation in the early stage by containing 7,8,4-trihydroxyisoflavone, and can improve, prevent, and treat arteriosclerosis without side effects. Moreover, since the 7,8,4-trihydroxyisoflavone of the present invention, as a food-derived metabolite, is absorbed in vivo and metabolized, there is low side effect, and arteriosclerosis can be directly prevented or treated. Accordingly, compared to a conventional functional food and treating agent, arteriosclerosis can be more effectively prevented and treated. Furthermore, the present invention provides a food and pharmaceutical composition including the 7,8,4-trihydroxyisoflavone as an active ingredient, and thus a monocyte cell adhesion inhibiting effect is exhibited in a vascular endothelial cell. Accordingly, arteriosclerosis can be effectively prevented and treated.
Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
<P>PROBLEM TO BE SOLVED: To provide a compounded composition which improves the antimicrobial disinfectant actions of a cationic surfactant having antimicrobial disinfectant actions, realizes effective antimicrobial disinfectant actions in a low concentration, and is highly safe for skins, eyes, and the like.  <P>SOLUTION: The compounded composition comprises a specific cationic surfactant having antimicrobial disinfectant actions and a specified nonionic surfactant. The weight concentration of the cationic surfactant is preferably 0.1 to 5.0 ppm, and the amount of the nonionic surfactant is preferably ≥3 pts.wt. per pt.wt. of the cationic surfactant.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The investigated product mIntense L+AS was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14 day intervals.
The study will include a Screening/Baseline Period, a Treatment Period, and a Post-treatment Follow-up Period. During the Screening Period, subjects will be selected for the study on the basis of inclusion and exclusion criteria (see below). A screening computed tomography scan to exclude brain bleeding will be performed. The patient's informed consent will be obtained. The patient will be randomly allocated to DP-b99 or placebo. Immediately after this randomization and baseline assessments (lab tests and ECG), subjects will be given a 2-hour intra-venous infusion of DP-b99 or placebo. Additional 3 such infusions will then be given daily to a total of 4 consecutive treatment days, which make up the "Treatment Period". Throughout the 4-day Treatment Period the treatment's safety and the National Institutes of Health Stroke Scale (NIHSS) score will be evaluated daily. (The NIHSS assesses certain abilities of the patient, e.g. strength, speech, vision and coordination). If their condition requires, patients may have to stay in hospital more than these 4 days, regardless of their participation in the study.Subjects will be further assessed for NIHSS score changes and safety (lab tests and ECG) during the Post-treatment Follow-up Period, with data collected 30 and 90 days after the stroke. Other outcome scales (Barthel Index and Modified Rankin Scale) will be also used in the Day 30 and Day 90 visits
ABSTRACT OF THE DISCLOSURE   In accordance with the present invention, a method is disclosed for the remediation of scar tissue in a human or an animal by introducing into the scar tissue or into tissue adjacent the scar tissue a remedial composition comprising a bioactive material selected from naturally occurring growth factors, synthetic growth factors, active peptide segments of naturally occurring and synthetic growth factors, and mixtures thereof. Typically the remedial composition includes a biodegradable or non-biodegradable support matrix material to provide for timed release of the bioactive material. Preferably, the support matrix material is biodegradable and is selected from the group consisting of collagen, glycosaminoglycan, gelatin, albumin, hyaluronic acid, heparin, oxidized cellulose, dextran, polyglycolic acid, polylactic acid, polyanhydride and mixtures thereof. Most scar tissue, particularly in human beings, is very dense and is difficult for the remedial composition described above to penetrate. To render the scar tissue less dense and to spatially expand the scar tissue fibrils, it is preferable to introduce into the scar tissue a softening, expanding composition as well as the remedial composition containing the bioactive material. The softening, expanding composition can be introduced simultaneously with introduction of the remedial composition; however, it is preferable that the softening, expanding composition be introduced prior to the remedial composition. A preferred softening, expanding composition includes at least one dried collagen-comprising polymer, at least one polymer hydrogel and a non-aqueous liquid carrier material.
FENTANYL TRANSDERMAL SYSTEM CII

Rx Only

IMPORTANT:

• Keep fentanyl transdermal system in a safe place away from children and pets. Accidental use by a child or pet is a medical emergency and may result in death. If a child or pet accidentally uses fentanyl transdermal system, get emergency help right away.

• Make sure you read the separate “Instructions for Applying a Fentanyl Transdermal System.” Always use a fentanyl transdermal system the right way. Fentanyl transdermal system can cause serious breathing problems and death, especially if it is used the wrong way.

• Fentanyl transdermal system is a federally controlled substance (C-II) because it can be abused. Keep fentanyl transdermal system in a safe place to prevent theft. Selling or giving away fentanyl transdermal system may harm others, and is against the law.

• Tell your doctor if you (or a family member) have ever abused or been dependent on alcohol, prescription medicines or street drugs.

Read the Medication Guide that comes with fentanyl transdermal system before you start using it and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Make sure you read and understand all the instructions for using fentanyl transdermal system. Do not use fentanyl transdermal system unless you understand everything. Talk to your healthcare provider if you have questions.